MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients.

This publication has 19 references indexed in Scilit:

• Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast Cancer
  New England Journal of Medicine, 2000
• Classification of isolated tumor cells and micrometastasis
  Cancer, 1999
• Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study
  The Lancet, 1999
• Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
  Immunology Today, 1997
• Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases
  The Lancet, 1996
• Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer
  Nature Medicine, 1995
• Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases
  Clinical & Experimental Metastasis, 1995
• Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells
  Histochemistry and Cell Biology, 1993
• Can the HLA phenotype be used as a prognostic factor in breast carcinomas?
  International Journal of Cancer, 1991
• Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).
  Journal of Histochemistry & Cytochemistry, 1984